摘要
目的 探讨重组人p53腺病毒治疗非小细胞肺癌并发恶性胸腔积液的疗效.方法 2006年1月至2009年12月广州医学院第一附属医院肿瘤血液中心和广州呼吸疾病研究所的96例恶性胸腔积液患者完全随机分为治疗组（46例,常规GP方案化疗,抽胸水后用重组人p53腺病毒胸腔注入）和对照组（50例,常规GP方案化疗,抽胸水后用A群链球菌胸腔注入）,观察两组患者的疗效和不良反应.结果 治疗组与对照组疗效差异无统计学意义,治疗组近期有效率71.7%（33/46）,但局部不良反应胸痛和咳嗽加重明显小于对照组（4.3%比20.O%,4.3%比22.O%,均P＜0.05）.结论 应用重组人p53腺病毒治疗恶性胸腔积液安全有效,不良反应比A群链球菌低.
Objective To explore the efficacy of rAd-p53 in malignant pleural effusion associated with non-small cell lung cancer（NSCLC）.Methods Ninty-six patients with malignant pleural effusion treated in Department of Hematology and Institute of Respiratory Diseases,The First Affiliated Hospital,Guangzhou Medical College,between January 2006 and December 2009,were randomized into intrapleural injection with rAd-p53（treatment group,n=46）or with Group A streptococcus preparation（control group,n=50）after proper drainage of pleural effusion,as an add-on therapy to the conventional gemcitabine and cisplatin chemotherapy.The therapeutic effects and adverse reactions in two groups were studied.Results There was no significant difference in therapeutic efficacy between two groups.The treatment group showed a short-term efficiency rate（RR）of 71.7%（33/46）,and less topical local side effects（chest pain and worsened cough）as compared with control group（4.3% vs 20.O%,4.3% vs 22.0%,both P〈0.05）.Conclusion The intrapleural injection with rAd-p53 is safe and effective in treatment of malignant pleural effusion,and may result in fewer side effects compamd with the use of group A streptococcus preparation.
出处
《中华生物医学工程杂志》
CAS
2011年第2期170-173,共4页
Chinese Journal of Biomedical Engineering
基金
基金项目：广东省科技计划项目（2006836002024）
广州市医药卫生科技项目（2008-YB-154）
关键词
腺病毒科
链球菌科
癌
非小细胞肺
胸腔积液
恶性
治疗结果
Adenoviridae
Streptococcaceae
Carcinoma,non-small-cell lung
Pleural effusion,malignant
Treatment outcome
